Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.
Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS; UpFrontPSMA Study Team. Azad AA, et al. Lancet Oncol. 2024 Oct;25(10):1267-1276. doi: 10.1016/S1470-2045(24)00440-6. Epub 2024 Sep 15. Lancet Oncol. 2024. PMID: 39293461 Clinical Trial.
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T.
Buteau JP, Kostos L, Alipour R, Jackson P, McInstosh L, Emmerson B, Haskali MB, Xie J, Medhurst E, Ravi R, Gonzalez BD, Fettke H, Blyth B, Furic L, Owen K, Sandhu S, Murphy DG, Azad AA, Hofman MS. Buteau JP, et al. Among authors: kostos l. J Nucl Med. 2024 Aug 1;65(8):1231-1238. doi: 10.2967/jnumed.124.267650. J Nucl Med. 2024. PMID: 38991752
Combination Strategies and Targeted Radionuclide Therapies.
Jewell K, Kostos L, Emmerson B, Hofman MS. Jewell K, et al. Among authors: kostos l. Semin Nucl Med. 2024 Jul;54(4):612-621. doi: 10.1053/j.semnuclmed.2024.05.011. Epub 2024 Jun 19. Semin Nucl Med. 2024. PMID: 38897821 Free article. Review.
Role of FDG PET/CT in Management of Patients with Prostate Cancer.
Sutherland DEK, Azad AA, Murphy DG, Eapen RS, Kostos L, Hofman MS. Sutherland DEK, et al. Among authors: kostos l. Semin Nucl Med. 2024 Jan;54(1):4-13. doi: 10.1053/j.semnuclmed.2023.06.005. Epub 2023 Jul 1. Semin Nucl Med. 2024. PMID: 37400321 Review.
KIT as a therapeutic target in neuroendocrine prostate cancer.
Azad AA, Kostos L, Agarwal N. Azad AA, et al. Among authors: kostos l. Cancer Cell. 2022 Nov 14;40(11):1266-1268. doi: 10.1016/j.ccell.2022.10.010. Epub 2022 Nov 3. Cancer Cell. 2022. PMID: 36332623 Free article.
19 results